A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objectives: There is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed, MEDLINE, PsycINFO, the Cochrane Central Register of Controlled Trials, Embase, and CINAHL for randomised controlled trials of methylenedioxymethamphetamine and psilocybin with either inactive or active controls. Methods: Outcomes were psychiatric symptoms measured by standardised, validated and internationally recognised instruments at least 2 weeks following drug administration, Quality was independently assessed using the Cochrane risk of bias assessment tool and Grading of Recommendations Assessment, Development and Evaluation framework. Results: There were eight studies on methylenedioxymethamphetamine and six on psilocybin. Diagnoses included post-traumatic stress disorder, long-standing/treatment-resistant depression, obsessive-compulsive disorder, social anxiety in adults with autism, and anxiety or depression in life-threatening disease. The most information and strongest association was for the change in methylenedioxymethamphetamine scores compared to active controls in post-traumatic stress disorder ( k = 4; standardised mean difference = −0.86; 95% confidence interval = [−1.23, −0.50]; p < 0.0001). There were also small benefits for social anxiety in adults with autism. Psilocybin was superior to wait-list but not niacin (active control) in life-threatening disease anxiety or depression. It was equally as effective as escitalopram in long-standing depression for the primary study outcome and superior for most of the secondary outcomes in analyses uncorrected for multiple comparisons. Both agents were well tolerated in supervised trials. Trial quality varied with only small proportions of potential participants included in the randomised phase. Overall certainty of evidence was low or very low using the Grading of Recommendations Assessment, Development and Evaluation framework. Conclusion: Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An effect size primer: A guide for clinicians and researchers.
Ferguson, C. J. (2009) · Professional Psychology: Research and Practice · doi:10.1037/a0015808 · Cited by 3,467 · cited 2×
“For RRs, the equivalent values were 2.0, 3.0 and 4.0, respectively (Ferguson, 2009; Sullivan and Feinn, 2012).”
BackgroundMethodInfluentialGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 7×
“Among the six studies on psilocybin (n = 187 participants), three were for anxiety or depression for an LTD (n = 92), two for long-standing or TRD (n = 86) and one for obsessive-compulsive disorder (n = 9) (Table 2).”
BackgroundResultInfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 3×
“In addition, the field is rapidly evolving with the availability of more studies and data that were not included in previous reviews (Carhart-Harris et al., 2021; Davis et al., 2021; Mitchell et al., 2021; Wolfson et al., 2020).”
BackgroundResultEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 5×
“Twelve of the studies were described as double-blinded (Supplementary Table 2) while one used a wait-list control (Davis et al., 2021) and another made no mention of blinding (Moreno et al., 2006).”
BackgroundInfluentialPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 2×
“In a fifth study, there were no statistically significant differences between psilocybin and controls at the 2-week follow-up, although both groups showed longterm improvements following cross-over (Grob et al., 2011).”
BackgroundMDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 4×
“In the final study, there was no significant effect of dose on obsessive-compulsive symptoms possibly because of low numbers and unexpectedly high response to the lowdose placebo (25 μg/kg) (Moreno et al., 2006).”
BackgroundInfluentialMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 3×
“There were eight studies on MDMA (Bouso et al., 2008; Danforth et al., 2018; Mitchell et al., 2021; Mithoefer et al., 2011, 2018; Oehen et al., 2013; Ot’alora et al., 2018; Wolfson et al., 2020) and six on psilocybin (Carhart-Harris et al., 2021; Davis et al., 2021; Griffiths et al., 2016; Grob et…”
BackgroundResultInfluentialMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 1×
“Both drugs are agonists of 5-HT2 receptors (Rickli et al., 2016; Sard et al., 2005), and studies in humans suggest that 5HT2A receptor occupancy may be critical for the psychedelic experience of psilocybin (Madsen et al., 2019), although actions at other receptors could also be involved.”
Background
Cited by
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.168 · Cited by 150
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
Is good science leading the way in the therapeutic use of psychedelic drugs?
Hall, W. D., & Humphreys, K. (2022) · Psychological Medicine · doi:10.1017/s0033291722003191 · Cited by 17
“A recent systematic review and meta-analysis (Kisely, Connor, Somogyi, & Siskind, 2022) of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioral or developmental disorders noted limitations of this study.”
Metadata
- Authors
- Kisely, S., Connor, M., Somogyi, A. A., & Siskind, D.
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2022-03-12
- Volume
- 57
- Issue
- 3
- Pages
- 362-378
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W4220928043
- Cited by
- 38
- References
- 22
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. https://app.cochat.ai/papers/10.1177/00048674221083868
- The paper
- Kisely, S., Connor, M., Somogyi, A. A., & Siskind, D. (2023). A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/00048674221083868
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.